Friday, 16 October 2026European Markets

LOTUS BAKERIES Stock Was 16.18% Up On Monday

Loading stream...

(VIANEWS) - The Market ended the session with LOTUS BAKERIES (LOTB.BR) jumping 16.18% to €9,120.00 on Monday, following the last session's downward trend. BEL 20 rose 0.29% to €3,625.62, after two successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

LOTUS BAKERIES's last close was €7,850.00, 6.77% under its 52-week high of €8,420.00.

About LOTUS BAKERIES

Lotus Bakeries NV, together with its subsidiaries, engages in the provision of various snack products in Belgium and internationally. The company offers biscuits, cookies, crackers, gingerbreads, cakes, cake specialties, waffles, and pepparkakor biscuits. It also provides energy bars, protein flapjacks, protein nut bars, healthy snacks, ice creams, and spreads. The company sells its products under the Lotus, Lotus Biscoff, nakd, TREK, BEAR, Kiddylicious, Peter's Yard, Dinosaurus, Peijnenburg, Snelle Jelle, Annas, Lotus Suzy, Lotus Tartélice lemon, Kung Oscar, and Urban Fruit brands. The company was founded in 1932 and is headquartered in Lembeke, Belgium. Lotus Bakeries NV is a subsidiary of Stichting Administratiekantoor van Aandelen Lotus Bakeries.

Earnings Per Share

As for profitability, LOTUS BAKERIES has a trailing twelve months EPS of €137.38.

PE Ratio

LOTUS BAKERIES has a trailing twelve months price to earnings ratio of 66.39. Meaning, the purchaser of the share is investing €66.39 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.81%.

More news about LOTUS BAKERIES (LOTB.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com